Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey.
Ouali K, Turpin A, Neuzillet C, Rousseau B, Garcia-Larnicol ML, Tournigand C, Samalin E, Taieb J, André T, Cohen R. Ouali K, et al. Among authors: samalin e. Clin Colorectal Cancer. 2021 Mar;20(1):79-83.e4. doi: 10.1016/j.clcc.2020.11.004. Epub 2020 Nov 14. Clin Colorectal Cancer. 2021. PMID: 33281064 Free article.
Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort.
Pernot S, Mitry E, Samalin E, Dahan L, Dalban C, Ychou M, Seitz JF, Turki H, Mazard T, Zaanan A, Lepère C, Vaillant JN, Landi B, Rougier P, Taieb J. Pernot S, et al. Among authors: samalin e. Gastric Cancer. 2014 Apr;17(2):341-7. doi: 10.1007/s10120-013-0266-6. Epub 2013 Jun 6. Gastric Cancer. 2014. PMID: 23739764
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
Samalin E, Bouché O, Thézenas S, Francois E, Adenis A, Bennouna J, Taieb J, Desseigne F, Seitz JF, Conroy T, Galais MP, Assenat E, Crapez E, Poujol S, Bibeau F, Boissière F, Laurent-Puig P, Ychou M, Mazard T. Samalin E, et al. Br J Cancer. 2014 Mar 4;110(5):1148-54. doi: 10.1038/bjc.2013.813. Epub 2014 Jan 9. Br J Cancer. 2014. PMID: 24407191 Free PMC article. Clinical Trial.
Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
Soularue É, Cohen R, Tournigand C, Zaanan A, Louvet C, Bachet JB, Hentic O, Samalin E, Chibaudel B, de Gramont A, André T; for GERCOR. Soularue É, et al. Among authors: samalin e. Bull Cancer. 2015 Apr;102(4):324-31. doi: 10.1016/j.bulcan.2014.08.001. Epub 2015 Mar 3. Bull Cancer. 2015. PMID: 25744576
Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study.
Mary F, Zaanan A, Boige V, Artru P, Samalin E, Coriat R, Bachet JB, Boubaya M, Benallaoua M, Tougeron D, Afchain P, Locher C, Baumgaertner I, Lecaille C, des Guetz G, Aparicio T; AGEO (Association des Gastro-Entérologues Oncologues). Mary F, et al. Among authors: samalin e. Dig Liver Dis. 2016 Dec;48(12):1498-1502. doi: 10.1016/j.dld.2016.07.022. Epub 2016 Aug 9. Dig Liver Dis. 2016. PMID: 27623185
Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.
Pernot S, Badoual C, Terme M, Castan F, Cazes A, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Bachet JB, Borg C, Ducreux M, Marcheteau E, Stanbury T, Gourgou S, Malka D, Taieb J. Pernot S, et al. Among authors: samalin e. Eur J Cancer. 2017 Jul;79:15-22. doi: 10.1016/j.ejca.2017.03.036. Epub 2017 Apr 26. Eur J Cancer. 2017. PMID: 28456090 Clinical Trial.
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Kim S, Jary M, André T, Vendrely V, Buecher B, François E, Bidard FC, Dumont S, Samalin E, Peiffert D, Pernot S, Baba-Hamed N, El Hajbi F, Bouché O, Desrame J, Parzy A, Zoubir M, Louvet C, Bachet JB, Nguyen T, Abdelghani MB, Smith D, De La Fouchardière C, Aparicio T, Bennouna J, Gornet JM, Jacquin M, Bonnetain F, Borg C. Kim S, et al. Among authors: samalin e. BMC Cancer. 2017 Aug 25;17(1):574. doi: 10.1186/s12885-017-3566-0. BMC Cancer. 2017. PMID: 28841909 Free PMC article. Clinical Trial.
Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study).
Zaanan A, Samalin E, Aparicio T, Bouche O, Laurent-Puig P, Manfredi S, Michel P, Monterymard C, Moreau M, Rougier P, Tougeron D, Taieb J, Louvet C. Zaanan A, et al. Among authors: samalin e. Dig Liver Dis. 2018 Apr;50(4):408-410. doi: 10.1016/j.dld.2018.01.119. Epub 2018 Mar 1. Dig Liver Dis. 2018. PMID: 29409778 Clinical Trial.
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S, François E, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, De La Fouchardiere C, Smith D, Deberne M, Spehner L, Badet N, Adotevi O, Anota A, Meurisse A, Vernerey D, Taieb J, Vendrely V, Buecher B, Borg C. Kim S, et al. Among authors: samalin e. Lancet Oncol. 2018 Aug;19(8):1094-1106. doi: 10.1016/S1470-2045(18)30321-8. Epub 2018 Jul 2. Lancet Oncol. 2018. PMID: 30042063 Clinical Trial.
71 results